These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1722166)

  • 1. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
    Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
    Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Benign prostatic hyperplasia--the outcome of age-induced alteration of androgen-estrogen balance?].
    Weisser H; Krieg M
    Urologe A; 1997 Jan; 36(1):3-9. PubMed ID: 9123678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
    Isaacs JT
    J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5alpha-reductase activity in the prostate.
    Steers WD
    Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxytocin and prostatic function.
    Nicholson HD; Jenkin L
    Adv Exp Med Biol; 1995; 395():529-38. PubMed ID: 8714010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
    Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
    J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign prostatic hyperplasia: pathogenesis and medical therapy.
    Geller J
    J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
    Isaacs JT; Coffey DS
    Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and androgen signaling in the pathogenesis of BPH.
    Ho CK; Habib FK
    Nat Rev Urol; 2011 Jan; 8(1):29-41. PubMed ID: 21228820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
    Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer.
    Voigt KD; Bartsch W
    J Steroid Biochem; 1986 Nov; 25(5B):749-57. PubMed ID: 2433505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.